Literature DB >> 18802019

Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.

Ralph Burkhardt1, Eimear E Kenny, Jennifer K Lowe, Andrew Birkeland, Rebecca Josowitz, Martha Noel, Jacqueline Salit, Julian B Maller, Itsik Pe'er, Mark J Daly, David Altshuler, Markus Stoffel, Jeffrey M Friedman, Jan L Breslow.   

Abstract

UNLABELLED: Background- Variation in LDL-cholesterol (LDL-C) among individuals is a complex genetic trait involving multiple genes and gene-environment interactions. METHODS AND
RESULTS: In a genome-wide association study (GWAS) to identify genetic variants influencing LDL-C in an isolated population from Kosrae, we observed associations for SNPs in the gene encoding 3hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase (HMGCR). Three of these SNPs (rs7703051, rs12654264, and rs3846663) met the statistical threshold of genome-wide significance when combined with data from the Diabetes Genetics Initiative GWAS. We followed up the association results and identified a functional SNP in intron13 (rs3846662), which was in linkage disequilibrium with the SNPs of genome-wide significance and affected alternative splicing of HMGCR mRNA. In vitro studies in human lymphoblastoid cells demonstrated that homozygosity for the rs3846662 minor allele was associated with up to 2.2-fold lower expression of alternatively spliced HMGCR mRNA lacking exon13, and minigene transfection assays confirmed that allele status at rs3846662 directly modulated alternative splicing of HMGCR exon13 (42.9+/-3.9 versus 63.7+/-1.0%Deltaexon13/total HMGCR mRNA, P=0.02). Further, the alternative splice variant could not restore HMGCR activity when expressed in HMGCR deficient UT-2 cells.
CONCLUSIONS: We identified variants in HMGCR that are associated with LDL-C across populations and affect alternative splicing of HMGCR exon13.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802019      PMCID: PMC2764366          DOI: 10.1161/ATVBAHA.108.172288

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  30 in total

Review 1.  Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility.

Authors:  J L Breslow
Journal:  Annu Rev Genet       Date:  2000       Impact factor: 16.830

2.  Epidemiology and factor analysis of obesity, type II diabetes, hypertension, and dyslipidemia (syndrome X) on the Island of Kosrae, Federated States of Micronesia.

Authors:  D Shmulewitz; S B Auerbach; T Lehner; M L Blundell; J D Winick; L D Youngman; V Skilling; S C Heath; J Ott; M Stoffel; J L Breslow; J M Friedman
Journal:  Hum Hered       Date:  2001       Impact factor: 0.444

Review 3.  Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.

Authors:  Daniel J Rader; Jonathan Cohen; Helen H Hobbs
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 4.  Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations.

Authors:  K Kuulasmaa; H Tunstall-Pedoe; A Dobson; S Fortmann; S Sans; H Tolonen; A Evans; M Ferrario; J Tuomilehto
Journal:  Lancet       Date:  2000-02-26       Impact factor: 79.321

Review 5.  The road to genome-wide association studies.

Authors:  Leonid Kruglyak
Journal:  Nat Rev Genet       Date:  2008-02-19       Impact factor: 53.242

Review 6.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

7.  Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis.

Authors:  E S Istvan; M Palnitkar; S K Buchanan; J Deisenhofer
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

8.  Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.

Authors:  Ronald M Krauss; Lara M Mangravite; Joshua D Smith; Marisa W Medina; Dai Wang; Xiuqing Guo; Mark J Rieder; Joel A Simon; Steven B Hulley; David Waters; Mohammed Saad; Paul T Williams; Kent D Taylor; Huiying Yang; Deborah A Nickerson; Jerome I Rotter
Journal:  Circulation       Date:  2008-03-10       Impact factor: 29.690

9.  Candidate genes involved in cardiovascular risk factors by a family-based association study on the island of Kosrae, Federated States of Micronesia.

Authors:  Zhihua Han; Simon C Heath; Dvora Shmulewitz; Wentian Li; Steve B Auerbach; Maude L Blundell; Thomas Lehner; Jurg Ott; Markus Stoffel; Jeffrey M Friedman; Jan L Breslow
Journal:  Am J Med Genet       Date:  2002-07-01

Review 10.  Alternative splicing: multiple control mechanisms and involvement in human disease.

Authors:  Javier F Cáceres; Alberto R Kornblihtt
Journal:  Trends Genet       Date:  2002-04       Impact factor: 11.639

View more
  63 in total

1.  Genomics: The search for association.

Authors:  Monya Baker
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

2.  Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia.

Authors:  Ruth Cano-Corres; Beatriz Candás-Estébanez; Ariadna Padró-Miquel; Marta Fanlo-Maresma; Xavier Pintó; Pedro Alía-Ramos
Journal:  J Clin Lab Anal       Date:  2018-05-07       Impact factor: 2.352

Review 3.  Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy.

Authors:  W Sadee; D Wang; A C Papp; J K Pinsonneault; R M Smith; R A Moyer; A D Johnson
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

Review 4.  Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics.

Authors:  Christopher C Imes; Melissa A Austin
Journal:  Biol Res Nurs       Date:  2012-04-23       Impact factor: 2.522

Review 5.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

6.  Systematic haplotype analysis resolves a complex plasma plant sterol locus on the Micronesian Island of Kosrae.

Authors:  Eimear E Kenny; Alexander Gusev; Kaitlin Riegel; Dieter Lütjohann; Jennifer K Lowe; Jacqueline Salit; Julian B Maller; Markus Stoffel; Mark J Daly; David M Altshuler; Jeffrey M Friedman; Jan L Breslow; Itsik Pe'er; Ephraim Sehayek
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

7.  Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy.

Authors:  Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar
Journal:  Ann Med       Date:  2020-08-24       Impact factor: 4.709

Review 8.  The role of HMGCR alternative splicing in statin efficacy.

Authors:  Marisa Wong Medina; Ronald M Krauss
Journal:  Trends Cardiovasc Med       Date:  2009-07       Impact factor: 6.677

9.  PharmGKB: very important pharmacogene--HMGCR.

Authors:  Marisa Wong Medina; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-02       Impact factor: 2.089

10.  Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.

Authors:  Lei Cao; Hui-Fu Wang; Lin Tan; Fu-Rong Sun; Meng-Shan Tan; Chen-Chen Tan; Teng Jiang; Jin-Tai Yu; Lan Tan
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.